[The effects of imatinib mesylate on immune globulin and T cell subset in patients with chronic myelocytic leukemia].
Rui-rui
RR
Gui
Yan-li
YL
Zhang
Bai-jun
BJ
Fang
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007136:Immunoglobulins / Q000378:metabolism*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets
D001549:Benzamides; D007136:Immunoglobulins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate